Hit enter to search or ESC to close
Vallon PharmaceuticalsVallon PharmaceuticalsVallon PharmaceuticalsVallon PharmaceuticalsVallon Pharmaceuticals
  • About
    • Company Overview
    • Leadership
    • Collaborations
  • Technology
    • Stimulant Abuse
    • How it Works
    • Clinical Data
    • Publications
  • Pipeline
    • Overview
    • ADAIR
    • ADMIR
    • ADHD
    • Narcolepsy
  • Patient Resources
  • Newsroom
  • Investors
    • Investors
    • Press Releases
    • Events + Presentations
    • Company Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • News Alerts
  • Contact
Newsroom

News and Media

Menu
  • News Releses
  • Media Contact
  • News Alerts

Recent Press Releases

Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors
February 23, 2021

Vallon Pharmaceuticals Announces Closing of Initial Public Offering
February 12, 2021

Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
February 09, 2021

Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting
January 19, 2021

Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting
January 08, 2021

Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR
November 09, 2020

Media Contact

JTC Team, LLC
Jenene Thomas
(833) 475-8247
vallon@jtcir.com

Subscribe to Receive News Alerts

Full Name
Email *
Company/Organization
Select your notifications

Sign Up for Updates

© 2021 Vallon Pharmaceuticals | Terms of Use | Privacy Policy

ADAIR is an investigational new drug product and has not yet been approved by the FDA. All trademarks shown are the property of their respective owners.

  • About
    • Company Overview
    • Leadership
    • Collaborations
  • Technology
    • Stimulant Abuse
    • How it Works
    • Clinical Data
    • Publications
  • Pipeline
    • Overview
    • ADAIR
    • ADMIR
    • ADHD
    • Narcolepsy
  • Patient Resources
  • Newsroom
  • Investors
    • Investors
    • Press Releases
    • Events + Presentations
    • Company Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • News Alerts
  • Contact